|
TROGLITAZONE |
|
(±)-5-[4-[(6-Hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]benzyl]-2,4-thiazolidinedione; 5-(4-(6-Hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl)thiazolidine-2,4-dione; Prelay; Rezulin; Romglizone; |
|
|
| PRODUCT IDENTIFICATION |
|
|
CAS RN |
97322-87-7 |
|
EINECS RN |
|
|
FORMULA |
C24H27NO5S |
|
MOLE WEIGHT |
441.54 |
|
CLASSIFICATION |
Thiazolidinedione / Antidiabetic / Hypoglycemic agents |
|
|
| PHYSICAL AND CHEMICAL PROPERTIES |
|
|
PHYSICAL STATE |
white to slightly yellowish powder |
|
MELTING POINT |
|
|
BOILING POINT |
|
|
DENSITY |
|
|
SOLUBILITY IN WATER |
(soluble in dimethyl sulfoxide at 20 mg/ml, in ethanol at 10 mg/ml) |
|
pH |
|
|
VAPOR DENSITY |
|
|
REFRACTIVE INDEX |
|
|
FLASH POINT |
|
|
|
| STABILITY AND REACTIVITY | |
| STABILITY | Stable under normal conditions. |
|
INCOMPATIBLE MATERIALS |
Strong oxidizing agents |
| DECOMPOSITION PRODUCTS |
Carbon monoxide, Carbon dioxide, Nitrogen oxides. Sulphur oxides |
| POLYMERIZATION | Has not been reported |
|
NFPA RATINGS |
|
|
|
| SAFETY |
|
|
HAZARD NOTES |
Toxic, May impair fertility |
|
EYE |
May cause eye irritation. |
|
SKIN |
May be harmful if absorbed through skin. May cause skin irritation. |
|
INGESTION |
May be harmful if swallowed. |
|
INHALATION |
May be harmful if inhaled. May cause respiratory tract irritation. |
|
CHRONIC |
|
|
|
| TRANSPORT & REGULATORY INFORMATION |
|
|
UN NO. |
|
| HAZARD CLASS |
|
| PACKING GROUP |
|
| HAZARD SYMBOL |
|
|
RISK PHRASES |
22-24/25 |
|
SAFETY PHRASES |
|
|
|
| EXTERNAL LINKS & GENERAL INFORMATION | ||||||||||||||||||||||||||||||||||||||
|
Troglitazone:
An orally-active
thiazolidinedione with antidiabetic and hepatotoxic properties and potential
antineoplastic activity. Troglitazone activates peroxisome
proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated
transcription factor, thereby inducing cell differentiation and inhibiting cell
growth and angiogenesis. This agent also modulates the transcription of
insulin-responsive genes, inhibits macrophage and monocyte activation, and
stimulates adipocyte differentiation. (http://www.cancer.gov/)
Troglitazone is one of the thiazolidinedione (TZD) class of anti-diabetic drugs and a ligand for peroxisome proliferator-activated receptor γ (PPARγ). Troglitazone and other PPARγ ligands have been shown to inhibit cell proliferation and induce cell cycle arrest in a variety of cancer cells, and have been considered as potential tumor preventive and tumor therapeutic agents. Little is known, however, about how normal or initiated cells respond to these agents during mouse skin carcinogenesis. We report here that troglitazone and another TZD, ciglitazone, dramatically inhibited mitogen-induced cellular proliferation in normal mouse skin primary keratinocytes and in the C50 keratinocyte cell line. This was accompanied by induction of cell cycle G1 phase arrest and suppression of cyclin D1, cdk4, and cdk2 expression. Troglitazone suppressed cyclin D1 expression at multiple levels. In addition, we demonstrated that PPARγ was not expressed at functional levels in cultured mouse skin keratinocytes, and that the inhibitory effects of troglitazone on cellular proliferation and cyclin D1 expression in these cells were PPARγ -independent. Given the important role of keratinocyte proliferation in skin carcinogenesis, our data suggest that TZD may be useful tumor preventive agents in skin. (http://www.nature.com/) Thiazolidinedione is the base structure of a class of drugs for type 2 diabetes that lower the blood sugar by increasing the body's sensitivity to insulin. These drugs increase the HDL (good) cholesterol resulting in lower lipid levels and lower blood pressure (antihypertensives). Thiazolidinedione structure drugs:
|
|
|
| SALES SPECIFICATION |
|
|
APPEARANCE |
white to slightly yellowish powder |
|
PURITY |
98.0% min |
|
|
| PACKING |
|
|
|
|
| PRICE INFORMATION |
 |
